Janux Therapeutics
About:
Janux Therapeutics develops immunotherapies that generates immune responses to prevent tumors and not affecting a patient’s healthy tissue.
Website: https://www.januxrx.com
Top Investors: OrbiMed, RA Capital Management, Samsara BioCapital, Biotechnology Value Fund, Janus Henderson Investors
Description:
Janux Therapeutics develops immunotherapies that generate immune responses to prevent tumors and not affecting a patient’s healthy tissue. Janux technology targets all three stages of the anti-tumor immune response.
Total Funding Amount:
$549M
Headquarters Location:
La Jolla, California, United States
Founded Date:
2017-01-01
Founders:
David Campbell
Number of Employees:
51-100
Last Funding Date:
2024-02-29
IPO Status:
Public
© 2025 bioDAO.ai